Is Vor Biopharma (VOR) Undervalued Following Phase 3 Progress And A $150 Million Equity Plan?

Vor Biopharma (VOR) drew fresh attention after a cluster of updates, including third quarter results showing a much smaller net loss and a new US$150 million at the market equity program.

Vor Biopharma’s share price has been volatile, with a 7.72% 7 day share price return and a 3.09% 30 day gain but a 7% decline over 90 days, while the year to date share price return of 68.99% contrasts with a 1 year total shareholder return that is down 18.42%. This signals that recent enthusiasm around Phase 3 progress, IgA nephropathy data and the new equity program is building short term momentum against a still weak multi year track record.

Scan similar early-stage biotech stories showing fresh clinical momentum with the curated 19 high quality undiscovered gems that may be flying under most investors’ radar.

Vor Biopharma now sits on a sharp year to date surge, a cleaner loss profile and a fresh US$150 million equity tap. Does that mix still skew the risk reward toward new buyers at this price?

Most Popular Narrative: 50% Undervalued

Vor Biopharma’s most followed valuation story pegs fair value at $39.00 per share, roughly double the last close of $19.67. This frames today’s price in the context of ambitious late stage autoimmune drug plans.

Completion of enrollment in the global Phase 3 UPSTREAM trial for generalized myasthenia gravis, with topline data expected in the first half of 2027, positions Vor Biopharma for a potential future launch that could influence revenue growth and operating leverage if key endpoints are met and eventually support commercialization outside China.

See why 1 investors see Vor Biopharma as 50% undervalued.

Result: Fair Value of $39.00 (UNDERVALUED)

Still, Vor Biopharma’s story leans heavily on a single in-licensed drug and on Phase 3 readouts that, if disappointing, could quickly puncture the undervaluation case.

Find out about the key risks to this Vor Biopharma narrative.

Next Steps

Mixed signals like these are exactly when you want to check the details yourself and not rely on headlines or single metrics. To weigh Vor Biopharma’s upside potential against the concerns around it, start with the 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Vor Biopharma?

Broaden your watchlist now and pressure test your thesis on Vor Biopharma by lining it up against other opportunities filtered by quality, value and risk using the Simply Wall Street Screener.

• Target potential mispricings by scanning a curated pool of value opportunities through the 33 high quality undervalued stocks.
• Prioritize financial resilience and stress test your downside by sorting companies with strong fundamentals using the list of solid balance sheet and fundamentals (24 results).
• Protect your capital first by filtering for steadier names with lower overall risk scores using the 29 resilient stocks with low risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com